2seventy bio (TSVT) Financials

$4.97 +0.01 (+0.20%)

Closing price 04/15/2025 04:00 PM Eastern

Extended Trading

$4.97 0.00 (0.00%)

As of 04/15/2025 06:36 PM Eastern

Annual Income Statements for 2seventy bio

This table shows 2seventy bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-254	-218	-57
Consolidated Net Income / (Loss)	-254	-218	-57
Net Income / (Loss) Continuing Operations	-254	-218	-57
Total Pre-Tax Income	-254	-218	-57
Total Operating Income	-263	-238	-115
Total Gross Profit	90	98	38
Total Revenue	91	100	38
Operating Revenue	91	100	38
Total Cost of Revenue	1.73	2.10	0.00
Operating Cost of Revenue	1.73	2.10	0.00
Total Operating Expenses	353	336	110
Selling, General & Admin Expense	79	69	44
Research & Development Expense	249	231	77
Other Operating Expenses / (Income)	24	15	23
Impairment Charge	0.00	12	0.00
Restructuring Charge	0.00	8.61	12
Other Special Charges / (Income)	0.23	0.24	-45
Total Other Income / (Expense), net	8.99	20	15
Interest & Investment Income	2.93	12	11
Other Income / (Expense), net	6.06	7.63	4.35
Income Tax Expense	0.00	0.00	0.00
Basic Earnings per Share	($7.13)	($4.42)	($1.10)
Weighted Average Basic Shares Outstanding	35.64M	49.28M	52.22M
Diluted Earnings per Share	($7.13)	($4.42)	($1.10)
Weighted Average Diluted Shares Outstanding	35.64M	49.28M	52.22M
Weighted Average Basic & Diluted Shares Outstanding	50.19M	51.31M	52.34M

This table shows 2seventy bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-68	-23	-47	-42	-71	-57	-53	25	-9.39	-20
Consolidated Net Income / (Loss)	-68	-23	-47	-42	-72	-57	-53	25	-9.93	-20
Net Income / (Loss) Continuing Operations	-68	-23	-47	-42	-72	-57	-53	25	-9.93	-20
Total Pre-Tax Income	-68	-23	-47	-42	-72	-57	-53	25	-9.93	-20
Total Operating Income	-68	-27	-52	-48	-78	-60	-51	-27	-14	-23
Total Gross Profit	13	56	41	35	11	11	12	8.97	14	2.93
Total Revenue	13	56	42	36	12	11	12	8.97	14	2.93
Operating Revenue	13	56	42	36	12	11	12	8.97	14	2.93
Total Operating Expenses	81	83	93	83	89	71	69	-12	27	26
Selling, General & Admin Expense	20	19	21	19	13	16	13	9.86	13	8.52
Research & Development Expense	58	60	68	60	51	51	44	16	8.32	8.65
Other Operating Expenses / (Income)	3.58	4.02	3.65	3.61	4.41	3.15	8.73	3.45	5.77	4.61
Total Other Income / (Expense), net	0.49	4.07	4.69	5.90	6.33	3.11	3.51	3.96	4.01	3.75
Interest & Investment Income	1.11	1.49	2.05	3.09	3.63	3.65	2.86	2.53	2.86	2.63
Other Income / (Expense), net	-0.62	2.58	2.64	2.81	2.70	-0.53	0.65	1.43	1.15	1.11
Basic Earnings per Share	($1.76)	($0.15)	($1.08)	($0.83)	($1.40)	($1.11)	($1.01)	$0.48	($0.19)	($0.38)
Weighted Average Basic Shares Outstanding	38.57M	35.64M	43.47M	50.97M	51.18M	49.28M	52.07M	52.19M	52.26M	52.22M
Diluted Earnings per Share	($1.76)	($0.15)	($1.08)	($0.83)	($1.40)	($1.11)	($1.01)	$0.45	($0.19)	($0.35)
Weighted Average Diluted Shares Outstanding	38.57M	35.64M	43.47M	50.97M	51.18M	49.28M	52.07M	55.01M	52.26M	52.22M
Weighted Average Basic & Diluted Shares Outstanding	37.92M	50.19M	50.20M	50.46M	50.62M	51.31M	51.41M	51.50M	51.59M	52.34M

This table details how cash moves in and out of 2seventy bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-58	4.39	-3.82
Net Cash From Operating Activities	-228	-167	-85
Net Cash From Continuing Operating Activities	-228	-167	-85
Net Income / (Loss) Continuing Operations	-254	-218	-57
Consolidated Net Income / (Loss)	-254	-218	-57
Depreciation Expense	12	10	7.10
Non-Cash Adjustments To Reconcile Net Income	56	55	-20
Changes in Operating Assets and Liabilities, net	-42	-14	-15
Net Cash From Investing Activities	3.75	44	81
Net Cash From Continuing Investing Activities	3.75	44	81
Purchase of Property, Plant & Equipment	-31	-14	-0.71
Purchase of Investments	-148	-265	-153
Sale of Property, Plant & Equipment	-	0.00	43
Sale and/or Maturity of Investments	182	323	192
Net Cash From Financing Activities	166	127	0.42
Net Cash From Continuing Financing Activities	166	127	0.42
Issuance of Common Equity	166	127	0.00
Other Financing Activities, net	0.70	0.53	0.42

This table details how cash moves in and out of 2seventy bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-143	-56	123	-97	-5.53	-15	-20	55	-52	13
Net Cash From Operating Activities	-61	-48	-49	-33	-22	-64	-42	-23	-11	-9.47
Net Cash From Continuing Operating Activities	-61	-48	-49	-33	-22	-64	-42	-23	-11	-9.47
Net Income / (Loss) Continuing Operations	-68	-23	-47	-42	-72	-57	-53	25	-9.93	-20
Consolidated Net Income / (Loss)	-68	-23	-47	-42	-72	-57	-53	25	-9.93	-20
Depreciation Expense	2.38	2.33	2.26	2.24	2.76	3.03	2.11	1.68	1.66	1.66
Non-Cash Adjustments To Reconcile Net Income	20	16	10	11	26	7.80	13	-42	6.29	2.60
Changes in Operating Assets and Liabilities, net	-15	-43	-15	-3.73	22	-18	-4.36	-7.90	-8.52	5.79
Net Cash From Investing Activities	-82	-8.50	45	-65	16	48	22	78	-41	22
Net Cash From Continuing Investing Activities	-82	-8.50	45	-65	16	48	22	78	-41	22
Purchase of Investments	-94	-30	-39	-121	-84	-21	-23	-7.01	-92	-32
Sale and/or Maturity of Investments	25	33	89	61	103	70	45	43	50	54
Net Cash From Financing Activities	0.18	0.23	127	0.13	-0.08	0.25	0.39	-0.02	0.05	0.00
Net Cash From Continuing Financing Activities	0.18	0.23	127	0.13	-0.08	0.25	0.39	-0.02	0.05	0.00
Other Financing Activities, net	0.20	0.23	0.15	0.20	-0.08	0.25	0.39	-0.02	0.05	0.00

This table presents 2seventy bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	657	565	480
Total Current Assets	301	238	187
Cash & Equivalents	71	75	71
Short-Term Investments	195	142	104
Accounts Receivable	21	13	7.78
Prepaid Expenses	14	7.37	4.72
Plant, Property, & Equipment, net	56	58	34
Total Noncurrent Assets	300	270	258
Long-Term Investments	40	43	48
Intangible Assets	7.30	6.59	5.89
Other Noncurrent Operating Assets	241	220	204
Total Liabilities & Shareholders' Equity	657	565	480
Total Liabilities	346	310	269
Total Current Liabilities	80	60	40
Accounts Payable	7.21	6.03	1.06
Accrued Expenses	55	26	23
Current Deferred Revenue	3.00	15	0.00
Other Current Liabilities	15	13	16
Total Noncurrent Liabilities	266	250	229
Noncurrent Deferred Revenue	5.00	3.92	0.00
Other Noncurrent Operating Liabilities	261	246	229
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	310	255	211
Total Preferred & Common Equity	310	255	211
Preferred Stock	0.00	0.00	0.00
Total Common Equity	310	255	211
Common Stock	607	767	779
Retained Earnings	-294	-511	-568
Accumulated Other Comprehensive Income / (Loss)	-2.88	-0.20	0.09

This table presents 2seventy bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	709	742	706	641	511	518	504
Total Current Assets	349	390	334	277	213	225	218
Cash & Equivalents	127	194	96	90	57	112	60
Short-Term Investments	196	146	187	160	125	90	132
Accounts Receivable	12	41	44	20	12	18	22
Prepaid Expenses	14	8.64	6.73	7.12	6.70	4.87	3.81
Plant, Property, & Equipment, net	47	59	61	61	38	37	35
Total Noncurrent Assets	313	293	311	303	260	256	250
Long-Term Investments	1.41	39	61	72	38	40	38
Intangible Assets	7.48	7.13	6.95	6.77	6.42	6.24	6.06
Other Noncurrent Operating Assets	292	235	231	225	215	210	206
Total Liabilities & Shareholders' Equity	709	742	706	641	511	518	504
Total Liabilities	386	341	338	334	304	283	276
Total Current Liabilities	80	77	67	68	60	47	44
Accounts Payable	7.98	13	6.27	5.31	8.80	3.00	5.08
Accrued Expenses	52	44	36	37	22	29	23
Current Deferred Revenue	0.00	8.48	13	13	16	0.00	0.00
Other Current Liabilities	20	11	12	12	13	16	16
Total Noncurrent Liabilities	306	264	271	266	243	236	232
Noncurrent Deferred Revenue	41	6.31	17	16	2.45	0.00	0.00
Other Noncurrent Operating Liabilities	265	258	254	250	241	236	232
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	323	401	367	306	207	235	228
Total Preferred & Common Equity	323	401	367	306	207	235	228
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	323	401	367	306	207	235	228
Common Stock	598	744	752	762	772	774	777
Retained Earnings	-271	-341	-383	-454	-564	-539	-549
Accumulated Other Comprehensive Income / (Loss)	-3.89	-1.95	-1.43	-0.92	-0.34	-0.24	0.31

This table displays calculated financial ratios and metrics derived from 2seventy bio's official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	67.81%	9.72%	-62.28%
EBITDA Growth	11.02%	10.53%	52.67%
EBIT Growth	12.05%	10.54%	51.70%
NOPAT Growth	16.18%	9.70%	51.42%
Net Income Growth	13.02%	14.39%	73.69%
EPS Growth	42.68%	38.01%	75.11%
Operating Cash Flow Growth	-10.29%	26.86%	49.06%
Free Cash Flow Firm Growth	-33.74%	17.63%	53.41%
Invested Capital Growth	286.14%	-205.85%	-161.77%
Revenue Q/Q Growth	78.16%	-31.19%	-17.01%
EBITDA Q/Q Growth	12.54%	-19.03%	26.21%
EBIT Q/Q Growth	12.41%	-18.46%	25.65%
NOPAT Q/Q Growth	13.53%	-15.97%	24.11%
Net Income Q/Q Growth	12.96%	-18.31%	39.45%
EPS Q/Q Growth	25.11%	-27.75%	40.86%
Operating Cash Flow Q/Q Growth	4.07%	-10.61%	38.90%
Free Cash Flow Firm Q/Q Growth	0.00%	-21.92%	38.71%
Invested Capital Q/Q Growth	428.42%	70.48%	-360.87%
Profitability Metrics	-	-	-
Gross Margin	98.11%	97.91%	100.00%
EBITDA Margin	-268.37%	-218.85%	-274.65%
Operating Margin	-287.60%	-236.69%	-304.87%
EBIT Margin	-280.98%	-229.10%	-293.39%
Profit (Net Income) Margin	-277.78%	-216.73%	-151.20%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	98.86%	94.60%	51.54%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-18,129.72%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-18,108.79%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	18,053.89%	0.00%	0.00%
Return on Equity (ROE)	-75.83%	-76.91%	-24.56%
Cash Return on Invested Capital (CROIC)	-4,348.62%	0.00%	0.00%
Operating Return on Assets (OROA)	-36.30%	-37.64%	-21.26%
Return on Assets (ROA)	-35.89%	-35.61%	-10.96%
Return on Common Equity (ROCE)	-75.83%	-76.91%	-24.56%
Return on Equity Simple (ROE_SIMPLE)	-81.86%	-85.22%	-27.16%
Net Operating Profit after Tax (NOPAT)	-184	-166	-81
NOPAT Margin	-201.32%	-165.68%	-213.41%
Net Nonoperating Expense Percent (NNEP)	-20.94%	-18.11%	9.75%
Return On Investment Capital (ROIC_SIMPLE)	-	-65.15%	-38.33%
Cost of Revenue to Revenue	1.89%	2.09%	0.00%
SG&A Expenses to Revenue	86.83%	69.15%	116.01%
R&D to Revenue	271.85%	229.87%	203.15%
Operating Expenses to Revenue	385.71%	334.60%	291.40%
Earnings before Interest and Taxes (EBIT)	-257	-230	-111
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-246	-220	-104
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.14	0.00	0.72
Price to Tangible Book Value (P/TBV)	1.22	0.00	0.74
Price to Revenue (P/Rev)	3.88	0.00	4.01
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	11.21	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.54	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.00	-1.00	-1.04
Leverage Ratio	2.11	2.16	2.24
Compound Leverage Factor	2.09	2.04	1.16
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	-0.76	0.00	-1.64
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.77	3.98	4.67
Quick Ratio	3.60	3.85	4.55
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-191	-157	-73
Operating Cash Flow to CapEx	-740.47%	-1,203.45%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.13	0.16	0.07
Accounts Receivable Turnover	4.82	5.84	3.57
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	2.02	1.76	0.82
Accounts Payable Turnover	0.26	0.32	0.00
Days Sales Outstanding (DSO)	75.71	62.49	102.15
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	1,399.10	1,150.82	0.00
Cash Conversion Cycle (CCC)	-1,323.39	-1,088.33	102.15
Capital & Investment Metrics	-	-	-
Invested Capital	4.39	-4.65	-12
Invested Capital Turnover	90.06	-781.22	-4.50
Increase / (Decrease) in Invested Capital	6.75	-9.04	-7.52
Enterprise Value (EV)	49	0.00	-71
Market Capitalization	355	0.00	152
Book Value per Share	$8.19	$5.18	$4.09
Tangible Book Value per Share	$7.68	$5.05	$3.97
Total Capital	310	255	211
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-306	-260	-223
Capital Expenditures (CapEx)	31	14	-42
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-45	-39	-28
Debt-free Net Working Capital (DFNWC)	221	178	147
Net Working Capital (NWC)	221	178	147
Net Nonoperating Expense (NNE)	70	51	-24
Net Nonoperating Obligations (NNO)	-306	-260	-223
Total Depreciation and Amortization (D&A)	12	10	7.10
Debt-free, Cash-free Net Working Capital to Revenue	-49.38%	-38.85%	-72.87%
Debt-free Net Working Capital to Revenue	241.64%	177.30%	388.69%
Net Working Capital to Revenue	241.64%	177.30%	388.69%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($7.13)	($4.42)	($1.10)
Adjusted Weighted Average Basic Shares Outstanding	35.64M	49.28M	52.22M
Adjusted Diluted Earnings per Share	($7.13)	($4.42)	($1.10)
Adjusted Weighted Average Diluted Shares Outstanding	35.64M	49.28M	52.22M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	50.19M	51.31M	52.34M
Normalized Net Operating Profit after Tax (NOPAT)	-184	-152	-104
Normalized NOPAT Margin	-201.14%	-151.11%	-274.56%
Pre Tax Income Margin	-277.78%	-216.73%	-151.20%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from 2seventy bio's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-30.37%	250.32%	393.78%	167.38%	-10.25%	-80.98%	-70.12%	-75.12%	12.46%	-72.61%
EBITDA Growth	-20.39%	61.22%	43.11%	42.23%	-8.84%	-157.47%	-3.39%	44.20%	84.65%	64.32%
EBIT Growth	-14.98%	59.66%	42.83%	41.80%	-9.09%	-145.47%	-2.93%	43.26%	83.01%	63.37%
NOPAT Growth	-4.80%	60.20%	42.91%	37.65%	-14.04%	-120.26%	1.08%	19.42%	82.12%	61.18%
Net Income Growth	-13.13%	62.04%	45.14%	45.64%	-5.54%	-145.53%	-12.02%	159.11%	86.13%	65.65%
EPS Growth	31.52%	94.09%	66.25%	58.91%	20.45%	-640.00%	6.48%	154.22%	86.43%	68.47%
Operating Cash Flow Growth	-39.82%	16.88%	33.20%	29.68%	64.51%	-33.62%	14.69%	29.15%	51.17%	85.10%
Free Cash Flow Firm Growth	-923.58%	0.00%	108.26%	-123.11%	61.72%	-27.59%	-111.40%	103.86%	43.09%	73.37%
Invested Capital Growth	97.71%	286.14%	-67.83%	219.24%	-1,077.56%	-205.85%	-154.46%	-128.59%	83.23%	-161.77%
Revenue Q/Q Growth	-0.55%	318.98%	-25.91%	-13.39%	-66.62%	-11.22%	16.39%	-27.89%	50.93%	-78.38%
EBITDA Q/Q Growth	10.38%	66.51%	-109.85%	8.28%	-68.84%	20.77%	15.74%	50.50%	53.55%	-84.16%
EBIT Q/Q Growth	11.13%	64.29%	-99.20%	7.93%	-66.59%	19.66%	16.47%	49.25%	50.12%	-73.22%
NOPAT Q/Q Growth	11.18%	60.20%	-90.04%	7.20%	-62.46%	23.13%	14.65%	24.40%	63.95%	-66.89%
Net Income Q/Q Growth	12.32%	65.91%	-103.18%	10.49%	-70.21%	20.68%	7.30%	147.23%	-139.93%	-96.52%
EPS Q/Q Growth	12.87%	91.48%	-620.00%	23.15%	-68.67%	20.71%	9.01%	144.55%	-142.22%	-84.21%
Operating Cash Flow Q/Q Growth	-30.49%	21.48%	-3.14%	33.46%	34.14%	-195.63%	34.15%	44.74%	54.61%	9.81%
Free Cash Flow Firm Q/Q Growth	-205.93%	75.41%	142.56%	-797.02%	47.51%	18.06%	96.20%	336.06%	-873.70%	61.65%
Invested Capital Q/Q Growth	93.17%	428.42%	409.50%	4.37%	-167.43%	70.48%	-162.13%	45.22%	60.45%	-360.87%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	97.19%	99.16%	98.46%	97.48%	95.42%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-496.83%	-39.71%	-112.48%	-119.12%	-602.48%	-537.63%	-389.23%	-267.19%	-82.24%	-700.51%
Operating Margin	-509.90%	-48.44%	-124.25%	-133.13%	-647.90%	-560.99%	-411.37%	-301.87%	-103.01%	-795.15%
EBIT Margin	-514.56%	-43.85%	-117.90%	-125.33%	-625.43%	-565.99%	-406.18%	-285.88%	-94.49%	-757.07%
Profit (Net Income) Margin	-506.26%	-41.20%	-112.97%	-116.76%	-595.30%	-531.84%	-423.59%	277.45%	-73.39%	-667.12%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	98.39%	93.95%	95.82%	93.16%	95.18%	93.97%	104.29%	-97.05%	77.67%	88.12%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-3,053.57%	-235.95%	-7,285.82%	0.00%	0.00%	-4,024.94%	-1,597.54%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-3,052.35%	-233.09%	-7,283.53%	0.00%	0.00%	-4,019.30%	-1,615.28%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	3,043.09%	207.85%	7,246.77%	0.00%	0.00%	3,952.04%	1,570.56%	0.00%	0.00%
Return on Equity (ROE)	-180.69%	-10.48%	-28.10%	-39.04%	-58.42%	-76.91%	-72.90%	-26.98%	-35.38%	-24.56%
Cash Return on Invested Capital (CROIC)	0.00%	-4,348.62%	-238.91%	-769.33%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-58.61%	-5.67%	-18.44%	-24.72%	-135.21%	-92.98%	-46.14%	-20.62%	-7.53%	-54.86%
Return on Assets (ROA)	-57.67%	-5.32%	-17.67%	-23.03%	-128.70%	-87.37%	-48.12%	20.01%	-5.85%	-48.34%
Return on Common Equity (ROCE)	-180.69%	-10.48%	-28.10%	-39.04%	-58.42%	-76.91%	-72.90%	-26.98%	-35.38%	-24.56%
Return on Equity Simple (ROE_SIMPLE)	-90.35%	0.00%	-53.69%	-49.02%	-60.01%	0.00%	-107.61%	-66.55%	-41.45%	0.00%
Net Operating Profit after Tax (NOPAT)	-48	-19	-36	-34	-55	-42	-36	-27	-9.76	-16
NOPAT Margin	-356.93%	-33.91%	-86.97%	-93.19%	-453.53%	-392.69%	-287.96%	-301.87%	-72.11%	-556.60%
Net Nonoperating Expense Percent (NNEP)	-10.46%	-1.23%	-2.86%	-2.29%	-5.28%	-5.25%	-5.64%	17.74%	-0.06%	-1.34%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-16.43%	-	-	-	-7.73%
Cost of Revenue to Revenue	2.81%	0.84%	1.54%	2.52%	4.58%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	146.26%	33.29%	49.78%	54.06%	108.06%	151.64%	101.80%	109.93%	95.20%	291.32%
R&D to Revenue	433.73%	107.06%	163.97%	166.39%	426.42%	479.38%	353.29%	178.58%	61.47%	295.73%
Operating Expenses to Revenue	607.09%	147.60%	222.71%	230.61%	743.32%	660.99%	551.79%	-133.28%	203.01%	895.15%
Earnings before Interest and Taxes (EBIT)	-69	-25	-49	-45	-75	-60	-51	-26	-13	-22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-67	-22	-47	-43	-73	-57	-48	-24	-11	-20
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.71	1.14	1.28	1.38	0.65	0.00	1.32	0.84	1.07	0.72
Price to Tangible Book Value (P/TBV)	1.81	1.22	1.34	1.46	0.66	0.00	1.37	0.87	1.09	0.74
Price to Revenue (P/Rev)	10.73	3.88	4.11	3.45	1.36	0.00	3.86	4.49	5.33	4.01
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	11.21	5.94	7.02	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	4.41	0.54	1.07	1.11	0.00	0.00	0.77	0.00	0.27	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.18	-1.00	-0.89	-1.00	-1.03	-1.00	-0.98	-0.97	-1.03	-1.04
Leverage Ratio	2.79	2.11	1.88	2.00	2.14	2.16	2.06	2.03	2.14	2.24
Compound Leverage Factor	2.75	1.99	1.80	1.86	2.04	2.03	2.15	-1.97	1.66	1.98
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.53	0.41	0.71	0.59	-0.41	0.00	-0.83	-0.70	-0.57	-1.03
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.37	3.77	5.07	4.99	4.08	3.98	3.52	4.76	4.95	4.67
Quick Ratio	4.19	3.60	4.96	4.89	3.97	3.85	3.20	4.66	4.87	4.55
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-105	-26	11	-77	-40	-33	-1.25	2.96	-23	-8.77
Operating Cash Flow to CapEx	-451.73%	-427.46%	-807.50%	-822.54%	-783.97%	-5,937.91%	-9,604.82%	0.00%	-30,897.06%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.11	0.13	0.16	0.20	0.22	0.16	0.11	0.07	0.08	0.07
Accounts Receivable Turnover	3.65	4.82	4.29	5.23	9.25	5.84	2.68	1.42	2.18	3.57
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.28	2.02	2.65	2.94	2.72	1.76	1.46	0.90	0.95	0.82
Accounts Payable Turnover	0.23	0.26	0.14	0.37	0.39	0.32	0.13	0.12	0.00	0.00
Days Sales Outstanding (DSO)	100.11	75.71	85.16	69.73	39.47	62.49	136.43	257.39	167.18	102.15
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	1,560.83	1,399.10	2,659.43	985.83	942.64	1,150.82	2,778.81	3,070.04	0.00	0.00
Cash Conversion Cycle (CCC)	-1,460.71	-1,323.39	-2,574.27	-916.11	-903.17	-1,088.33	-2,642.37	-2,812.65	167.18	102.15
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-1.34	4.39	22	23	-16	-4.65	-12	-6.68	-2.64	-12
Invested Capital Turnover	-1.72	90.06	2.71	78.18	-17.08	-781.22	13.98	5.29	-4.96	-4.50
Increase / (Decrease) in Invested Capital	57	6.75	-47	43	-14	-9.04	-35	-30	13	-7.52
Enterprise Value (EV)	227	49	133	164	-124	0.00	55	-44	12	-71
Market Capitalization	551	355	512	508	198	0.00	275	198	243	152
Book Value per Share	$8.53	$8.19	$8.00	$7.32	$6.07	$5.18	$4.04	$4.57	$4.43	$4.09
Tangible Book Value per Share	$8.02	$7.68	$7.61	$6.94	$5.94	$5.05	$3.92	$4.45	$4.31	$3.97
Total Capital	323	310	401	367	306	255	207	235	228	211
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-325	-306	-379	-344	-322	-260	-220	-241	-231	-223
Capital Expenditures (CapEx)	13	11	6.08	3.97	2.74	1.07	0.44	-43	0.03	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-54	-45	-27	-16	-41	-39	-29	-24	-18	-28
Debt-free Net Working Capital (DFNWC)	270	221	313	267	209	178	152	178	174	147
Net Working Capital (NWC)	270	221	313	267	209	178	152	178	174	147
Net Nonoperating Expense (NNE)	20	4.09	11	8.50	17	15	17	-52	0.17	3.23
Net Nonoperating Obligations (NNO)	-325	-306	-379	-344	-322	-260	-220	-241	-231	-223
Total Depreciation and Amortization (D&A)	2.38	2.33	2.26	2.24	2.76	3.03	2.11	1.68	1.66	1.66
Debt-free, Cash-free Net Working Capital to Revenue	-104.35%	-49.38%	-21.69%	-10.91%	-28.36%	-38.85%	-40.65%	-54.86%	-39.49%	-72.87%
Debt-free Net Working Capital to Revenue	524.82%	241.64%	250.94%	181.16%	143.44%	177.30%	214.09%	402.69%	382.25%	388.69%
Net Working Capital to Revenue	524.82%	241.64%	250.94%	181.16%	143.44%	177.30%	214.09%	402.69%	382.25%	388.69%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.76)	($0.15)	($1.08)	($0.83)	($1.40)	($1.11)	($1.01)	$0.48	($0.19)	($0.38)
Adjusted Weighted Average Basic Shares Outstanding	38.57M	35.64M	43.47M	50.97M	51.18M	49.28M	52.07M	52.19M	52.26M	52.22M
Adjusted Diluted Earnings per Share	($1.76)	($0.15)	($1.08)	($0.83)	($1.40)	($1.11)	($1.01)	$0.45	($0.19)	($0.35)
Adjusted Weighted Average Diluted Shares Outstanding	38.57M	35.64M	43.47M	50.97M	51.18M	49.28M	52.07M	55.01M	52.26M	52.22M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	37.92M	50.19M	50.20M	50.46M	50.62M	51.31M	51.41M	51.50M	51.59M	52.34M
Normalized Net Operating Profit after Tax (NOPAT)	-48	-19	-36	-34	-40	-42	-34	-48	-9.41	-16
Normalized NOPAT Margin	-356.67%	-33.84%	-86.85%	-93.09%	-332.98%	-392.33%	-269.41%	-533.51%	-69.50%	-556.60%
Pre Tax Income Margin	-506.26%	-41.20%	-112.97%	-116.76%	-595.30%	-531.84%	-423.59%	277.45%	-73.39%	-667.12%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About 2seventy bio's Financials

When does 2seventy bio's fiscal year end?

According to the most recent income statement we have on file, 2seventy bio's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has 2seventy bio's net income changed over the last 2 years?

2seventy bio's net income appears to be on a downward trend, with a most recent value of -$57.25 million in 2024, falling from -$254.15 million in 2022. The previous period was -$217.57 million in 2023.

What is 2seventy bio's operating income?

2seventy bio's total operating income in 2024 was -$115.43 million, based on the following breakdown:

Total Gross Profit: $37.86 million
Total Operating Expenses: $110.33 million

How has 2seventy bio revenue changed over the last 2 years?

Over the last 2 years, 2seventy bio's total revenue changed from $91.50 million in 2022 to $37.86 million in 2024, a change of -58.6%.

How much debt does 2seventy bio have?

2seventy bio's total liabilities were at $268.70 million at the end of 2024, a 13.4% decrease from 2023, and a 22.4% decrease since 2022.

How much cash does 2seventy bio have?

In the past 2 years, 2seventy bio's cash and equivalents has ranged from $71.03 million in 2022 to $74.96 million in 2023, and is currently $71.24 million as of their latest financial filing in 2024.

How has 2seventy bio's book value per share changed over the last 2 years?

Over the last 2 years, 2seventy bio's book value per share changed from 8.19 in 2022 to 4.09 in 2024, a change of -50.1%.

Remove Ads

Related Companies

This page (NASDAQ:TSVT) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

2seventy bio (TSVT) Financials

Frequently Asked Questions About 2seventy bio's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

2seventy bio (TSVT) Financials

Annual Income Statements for 2seventy bio

Quarterly Income Statements for 2seventy bio

Annual Cash Flow Statements for 2seventy bio

Quarterly Cash Flow Statements for 2seventy bio

Annual Balance Sheets for 2seventy bio

Quarterly Balance Sheets for 2seventy bio

Annual Metrics and Ratios for 2seventy bio

Quarterly Metrics and Ratios for 2seventy bio

Frequently Asked Questions About 2seventy bio's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools